Analyst firms · Morgan Stanley · ABVX

Morgan Stanley ABVX price target and rating history

Abivax SA (ABVX) · Health Care

Morgan Stanley rates Abivax SA (ABVX) Overweight with a $71 price target, as of its latest action on Jul 23, 2025. It has published 3 rating actions on ABVX since November 2023, including 1 upgrade and 0 downgrades.

Current rating
Overweight
Price target
$71
Median target, all firms
Too few
Actions on ABVX
3

Morgan Stanley price target on ABVX

$71$42$12202420252026
Morgan Stanley price target on ABVX, each point a stated target, November 2023 to July 2025.

Every Morgan Stanley rating on ABVX

How other firms rate ABVX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
JefferiesBuy$158Jul 1, 2026
WedbushNeutral$90Jun 2, 2026
Truist SecuritiesBuyNov 24, 2025

Questions about Morgan Stanley and ABVX

What is Morgan Stanley's price target for ABVX?
Morgan Stanley's latest stated price target for Abivax SA (ABVX) is $71, from its action on Jul 23, 2025.
What is Morgan Stanley's rating on ABVX?
Morgan Stanley rates ABVX Overweight, a bullish rating, as of Jul 23, 2025.
When did Morgan Stanley last change its view on ABVX?
On Jul 23, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $71.

More ABVX rating histories

All Morgan Stanley ratingsABVX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.